In adults ages 18 to 65 with type 2 diabetes, GLP-1 medicines lined up with about 3 to 4 extra optic-nerve injury cases per 10,000

What the research found

Study (records comparison, not a trial). Chintan Dave and colleagues at Rutgers report in Annals of Internal Medicine (DOI 10.7326/ANNALS-25-00860) on US adults ages 18 to 65 with type 2 diabetes who had recently started a glucose-lowering medicine. GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), lined up with about three to four additional ischemic optic neuropathy cases per 10,000 people over 18 months. The injury can cause sudden vision loss; about one third of patients regain some sight, usually in the first six months, and some loss often remains. Cases clustered in men and in ages 50 to 65. The authors say this is not proof the medicines caused the injury. It is not a reason to start or stop a prescription. Sudden vision changes need a clinician promptly. Not medical advice. Not a substitute for a prescribed medicine. Off-label use is clinician-only.

Evidence level: Animal study. Results in animals or cells often don't carry over to people.

Not medical advice. Not a substitute for a prescribed medicine. Off-label prescription use is clinician-only. VitaLonga does not diagnose, treat, or cure disease. Never start, stop, or replace a prescription with a supplement on the basis of a headline.

Read the original at Rutgers / Annals of Internal Medicine